A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

NCT00719472 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

451

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Rituximab
DRUG: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
DRUG: CVP (cyclophosphamide, vincristine, prednisone)
DRUG: Analgesic/antipyretic and antihistamine drugs

Sponsor

Genentech, Inc.